83281-53-2

Usage

Type

Organic compound

Common uses

Production of perfumes and flavorings, personal care products

Physical properties

Clear, pale yellow liquid

Odor

Sweet, floral, fruity

Other uses

Production of pharmaceuticals, intermediate in chemical synthesis

Safety precautions

Causes skin and eye irritation, store in cool, dry place away from ignition sources

Upstream product

• 99-06-9 3-Carboxyphenol 
• 106-95-6 allyl bromide 
• 107-18-6 allyl alcohol 
• 16446-73-4 3-(chlorocarbonyl)phenyl acetate 
• 1266100-36-0 C₁₂H₁₂O₄ 

Downstream Products

• 1025900-94-0 3-[3-(4-decyloxy-benzyloxy)-2-hydroxy-propoxy]-benzoic acid allyl ester 
• 408501-50-8 3-propenyl 3-[4-(4-decyloxyphenyl)-2-oxobutoxy]benzoate 
• 1023287-62-8 allyl 3-({3-[2-allyloxyphenyl]propanoyl}oxy)benzoate 
• 1023287-45-7 3-(allyloxycarbonyl)phenyl 3-allyloxybenzoate 
• 1266100-38-2 9H-fluoren-9-ylmethyl (2S,4R)-2-(3-[(allyloxy)-carbonyl]phenoxymethyl)-4-aminotetrahydro-1H-pyrrole-1-carboxylate hydrochloride 
• 1266100-39-3 4-(4-((N-((3R,5S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-5-((3-((allyloxy)carbonyl)phenoxy)methyl)pyrrolidin-3-yl)benzamido)methyl)-3,5-dimethoxyphenoxy)butanoic acid 
• 1266100-37-1 C₃₅H₃₈N₂O₇ 

Relevant academic research and scientific papers

COMPOUNDS AND THERAPEUTIC USES THEREOF

The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and a disease or disorder mediated and/or caused by an infective agent, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.

CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS

Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of formulae Ia and Ib are constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. These macrocycles Ia and Ib are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being the agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), ion channels and signal transduction pathways. In particular, these macrocycles act as antagonists of the motilin receptor, the FP receptor and the purinergic receptors P2Y1, as modulators of the serotonin receptor of subtype 5-HT2B, as blockers of the voltage-gated potassium channel Kv1.3 and as inhibitors of the β-catenin-dependent “canonical” Wnt pathway. Thus they are showing great potential as medicaments for a variety of diseases.

[Pd(μ-Br)(PtBu3)]2 as a highly active isomerization catalyst: Synthesis of enol esters from allylic esters

The dimeric Pd(I)-complex [Pd(μ-Br)(PtBu3)] 2 was found to be highly active for catalyzing double-bond migration in various substrates such as unsaturated ethers, alcohols, amides, and arenes, under mild conditions. It efficiently mediates the conversion of allylic esters into enol esters, rather than inserting into the allylic C-O bond. The broad applicability of this reaction was demonstrated with the synthesis of 22 functionalized enol esters.

Synthesis of novel aromatic macrolactones via ring closing metathesis of substituted phenylalkanoic acid allylic esters

(Chemical Equation Presented) Stable aromatic macrolactones have been synthesized and characterized from 2- and 3-substituted phenylalkanoic acid systems in modest yields.